APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Age Related Macular Degeneration Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Age Related Macular Degeneration Drugs Industry Growth and Trends Forecast to 2032

Report ID 173961290120 December 202595 pages

Choose your research edition.

Industry ResearchAge Related Macular Degeneration Drugs Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Age Related Macular Degeneration Drugs Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Age Related Macular Degeneration Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Age Related Macular Degeneration Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Age Related Macular Degeneration Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Age Related Macular Degeneration Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Age Related Macular Degeneration Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Age Related Macular Degeneration Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Age Related Macular Degeneration Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Age Related Macular Degeneration Drugs include Novartis, Roche, Bayer Healthcare, Regeneron Pharmaceuticals, Neurotech Pharmaceuticals and Allergan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Age Related Macular Degeneration Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Age Related Macular Degeneration Drugs market size, estimates, and forecasts are presented in terms of sales volume (W Tons) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Age Related Macular Degeneration Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Age Related Macular Degeneration Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Age Related Macular Degeneration Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Age Related Macular Degeneration Drugs Market by Company

Novartis

Roche

Bayer Healthcare

Regeneron Pharmaceuticals

Neurotech Pharmaceuticals

Allergan

Age Related Macular Degeneration Drugs Segment by Type

Eylea

Avastin

Squalamine

Conercept

Lampalizamab

Lucentis

Others

Age Related Macular Degeneration Drugs Segment by Application

50-60 Years Old

60-70 Years Old

Others

Age Related Macular Degeneration Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Age Related Macular Degeneration Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Age Related Macular Degeneration Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Age Related Macular Degeneration Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Age Related Macular Degeneration Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Age Related Macular Degeneration Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Eylea Table 2. Major Company of Avastin Table 3. Major Company of Squalamine Table 4. Major Company of Conercept Table 5. Major Company of Lampalizamab Table 6. Major Company of Lucentis Table 7. Major Company of Others Table 8. Global Age Related Macular Degeneration Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 9. Global Age Related Macular Degeneration Drugs Sales by Type (2021-2026) & (W Tons) Table 10. Global Age Related Macular Degeneration Drugs Sales Market Share in Volume by Type (2021-2026) Table 11. Global Age Related Macular Degeneration Drugs Sales by Type (2021-2026) & (US$ Million) Table 12. Global Age Related Macular Degeneration Drugs Sales Market Share in Value by Type (2021-2026) Table 13. Global Age Related Macular Degeneration Drugs Price by Type (2021-2026) & (US$/Ton) Table 14. Global Age Related Macular Degeneration Drugs Sales by Type (2027-2032) & (W Tons) Table 15. Global Age Related Macular Degeneration Drugs Sales Market Share in Volume by Type (2027-2032) Table 16. Global Age Related Macular Degeneration Drugs Sales by Type (2027-2032) & (US$ Million) Table 17. Global Age Related Macular Degeneration Drugs Sales Market Share in Value by Type (2027-2032) Table 18. Global Age Related Macular Degeneration Drugs Price by Type (2027-2032) & (US$/Ton) Table 19. North America Age Related Macular Degeneration Drugs Sales by Type (2021-2026) & (W Tons) Table 20. North America Age Related Macular Degeneration Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Europe Age Related Macular Degeneration Drugs Sales by Type (2021-2026) & (W Tons) Table 22. Europe Age Related Macular Degeneration Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Asia-Pacific Age Related Macular Degeneration Drugs Sales by Type (2021-2026) & (W Tons) Table 24. Asia-Pacific Age Related Macular Degeneration Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. Latin America Age Related Macular Degeneration Drugs Sales by Type (2021-2026) & (W Tons) Table 26. Latin America Age Related Macular Degeneration Drugs Sales by Type (2021-2026) & (US$ Million) Table 27. Middle East and Africa Age Related Macular Degeneration Drugs Sales by Type (2021-2026) & (W Tons) Table 28. Middle East and Africa Age Related Macular Degeneration Drugs Sales by Type (2021-2026) & (US$ Million) Table 29. Age Related Macular Degeneration Drugs Industry Trends Table 30. Age Related Macular Degeneration Drugs Industry Drivers Table 31. Age Related Macular Degeneration Drugs Industry Opportunities and Challenges Table 32. Age Related Macular Degeneration Drugs Industry Restraints Table 33. Global Age Related Macular Degeneration Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 34. Global Age Related Macular Degeneration Drugs Revenue Market Share by Company (2021-2026) Table 35. Global Age Related Macular Degeneration Drugs Sales by Company (2021-2026) & (W Tons) Table 36. Global Age Related Macular Degeneration Drugs Sales Share by Company (2021-2026) Table 37. Global Age Related Macular Degeneration Drugs Market Price by Company (2021-2026) & (US$/Ton) Table 38. Global Age Related Macular Degeneration Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 39. Global Age Related Macular Degeneration Drugs Major Company Production Sites and Headquarters Table 40. Global Age Related Macular Degeneration Drugs Company, Product Type & Application Table 41. Global Age Related Macular Degeneration Drugs Company Establishment Date Table 42. Global Company Market Concentration Ratio (CR5 and HHI) Table 43. Global Age Related Macular Degeneration Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 44. Global Age Related Macular Degeneration Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 45. Global Age Related Macular Degeneration Drugs Sales by Region (2021-2026) & (W Tons) Table 46. Global Age Related Macular Degeneration Drugs Sales Market Share in Volume by Region (2021-2026) Table 47. Global Age Related Macular Degeneration Drugs Sales by Region (2021-2026) & (US$ Million) Table 48. Global Age Related Macular Degeneration Drugs Sales Market Share in Value by Region (2021-2026) Table 49. Global Age Related Macular Degeneration Drugs Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 50. Global Age Related Macular Degeneration Drugs Sales by Region (2027-2032) & (W Tons) Table 51. Global Age Related Macular Degeneration Drugs Sales Market Share in Volume by Region (2027-2032) Table 52. Global Age Related Macular Degeneration Drugs Sales by Region (2027-2032) & (US$ Million) Table 53. Global Age Related Macular Degeneration Drugs Sales Market Share in Value by Region (2027-2032) Table 54. Global Age Related Macular Degeneration Drugs Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2027-2032) Table 55. Global Age Related Macular Degeneration Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 56. Global Age Related Macular Degeneration Drugs Sales by Application (2021-2026) & (W Tons) Table 57. Global Age Related Macular Degeneration Drugs Sales Market Share in Volume by Application (2021-2026) Table 58. Global Age Related Macular Degeneration Drugs Sales by Application (2021-2026) & (US$ Million) Table 59. Global Age Related Macular Degeneration Drugs Sales Market Share in Value by Application (2021-2026) Table 60. Global Age Related Macular Degeneration Drugs Price by Application (2021-2026) & (US$/Ton) Table 61. Global Age Related Macular Degeneration Drugs Sales by Application (2027-2032) & (W Tons) Table 62. Global Age Related Macular Degeneration Drugs Sales Market Share in Volume by Application (2027-2032) Table 63. Global Age Related Macular Degeneration Drugs Sales by Application (2027-2032) & (US$ Million) Table 64. Global Age Related Macular Degeneration Drugs Sales Market Share in Value by Application (2027-2032) Table 65. Global Age Related Macular Degeneration Drugs Price by Application (2027-2032) & (US$/Ton) Table 66. North America Age Related Macular Degeneration Drugs Sales by Application (2021-2026) & (W Tons) Table 67. North America Age Related Macular Degeneration Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Europe Age Related Macular Degeneration Drugs Sales by Application (2021-2026) & (W Tons) Table 69. Europe Age Related Macular Degeneration Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Asia-Pacific Age Related Macular Degeneration Drugs Sales by Application (2021-2026) & (W Tons) Table 71. Asia-Pacific Age Related Macular Degeneration Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. Latin America Age Related Macular Degeneration Drugs Sales by Application (2021-2026) & (W Tons) Table 73. Latin America Age Related Macular Degeneration Drugs Sales by Application (2021-2026) & (US$ Million) Table 74. Middle East and Africa Age Related Macular Degeneration Drugs Sales by Application (2021-2026) & (W Tons) Table 75. Middle East and Africa Age Related Macular Degeneration Drugs Sales by Application (2021-2026) & (US$ Million) Table 76. Novartis Company Information Table 77. Novartis Business Overview Table 78. Novartis Age Related Macular Degeneration Drugs Sales (W Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 79. Novartis Age Related Macular Degeneration Drugs Product Portfolio Table 80. Novartis Recent Development Table 81. Roche Company Information Table 82. Roche Business Overview Table 83. Roche Age Related Macular Degeneration Drugs Sales (W Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 84. Roche Age Related Macular Degeneration Drugs Product Portfolio Table 85. Roche Recent Development Table 86. Bayer Healthcare Company Information Table 87. Bayer Healthcare Business Overview Table 88. Bayer Healthcare Age Related Macular Degeneration Drugs Sales (W Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 89. Bayer Healthcare Age Related Macular Degeneration Drugs Product Portfolio Table 90. Bayer Healthcare Recent Development Table 91. Regeneron Pharmaceuticals Company Information Table 92. Regeneron Pharmaceuticals Business Overview Table 93. Regeneron Pharmaceuticals Age Related Macular Degeneration Drugs Sales (W Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 94. Regeneron Pharmaceuticals Age Related Macular Degeneration Drugs Product Portfolio Table 95. Regeneron Pharmaceuticals Recent Development Table 96. Neurotech Pharmaceuticals Company Information Table 97. Neurotech Pharmaceuticals Business Overview Table 98. Neurotech Pharmaceuticals Age Related Macular Degeneration Drugs Sales (W Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 99. Neurotech Pharmaceuticals Age Related Macular Degeneration Drugs Product Portfolio Table 100. Neurotech Pharmaceuticals Recent Development Table 101. Allergan Company Information Table 102. Allergan Business Overview Table 103. Allergan Age Related Macular Degeneration Drugs Sales (W Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 104. Allergan Age Related Macular Degeneration Drugs Product Portfolio Table 105. Allergan Recent Development Table 106. North America Age Related Macular Degeneration Drugs Market Size Growth Rate (CAGR) by Country (W Tons): 2021 VS 2025 VS 2032 Table 107. North America Age Related Macular Degeneration Drugs Sales by Country (2021-2026) & (W Tons) Table 108. North America Age Related Macular Degeneration Drugs Sales Market Share by Country (2021-2026) Table 109. North America Age Related Macular Degeneration Drugs Sales Forecast by Country (2027-2032) & (W Tons) Table 110. North America Age Related Macular Degeneration Drugs Sales Market Share Forecast by Country (2027-2032) Table 111. North America Age Related Macular Degeneration Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 112. North America Age Related Macular Degeneration Drugs Market Size by Country (2021-2026) & (US$ Million) Table 113. North America Age Related Macular Degeneration Drugs Market Share by Country (2021-2026) Table 114. North America Age Related Macular Degeneration Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 115. North America Age Related Macular Degeneration Drugs Market Share Forecast by Country (2027-2032) Table 116. Europe Age Related Macular Degeneration Drugs Market Size Growth Rate (CAGR) by Country (W Tons): 2021 VS 2025 VS 2032 Table 117. Europe Age Related Macular Degeneration Drugs Sales by Country (2021-2026) & (W Tons) Table 118. Europe Age Related Macular Degeneration Drugs Sales Market Share by Country (2021-2026) Table 119. Europe Age Related Macular Degeneration Drugs Sales Forecast by Country (2027-2032) & (W Tons) Table 120. Europe Age Related Macular Degeneration Drugs Sales Market Share Forecast by Country (2027-2032) Table 121. Europe Age Related Macular Degeneration Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 122. Europe Age Related Macular Degeneration Drugs Market Size by Country (2021-2026) & (US$ Million) Table 123. Europe Age Related Macular Degeneration Drugs Market Share by Country (2021-2026) Table 124. Europe Age Related Macular Degeneration Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 125. Europe Age Related Macular Degeneration Drugs Market Share Forecast by Country (2027-2032) Table 126. Asia-Pacific Age Related Macular Degeneration Drugs Market Size Growth Rate (CAGR) by Country (W Tons): 2021 VS 2025 VS 2032 Table 127. Asia-Pacific Age Related Macular Degeneration Drugs Sales by Country (2021-2026) & (W Tons) Table 128. Asia-Pacific Age Related Macular Degeneration Drugs Sales Market Share by Country (2021-2026) Table 129. Asia-Pacific Age Related Macular Degeneration Drugs Sales Forecast by Country (2027-2032) & (W Tons) Table 130. Asia-Pacific Age Related Macular Degeneration Drugs Sales Market Share Forecast by Country (2027-2032) Table 131. Asia-Pacific Age Related Macular Degeneration Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 132. Asia-Pacific Age Related Macular Degeneration Drugs Market Size by Country (2021-2026) & (US$ Million) Table 133. Asia-Pacific Age Related Macular Degeneration Drugs Market Share by Country (2021-2026) Table 134. Asia-Pacific Age Related Macular Degeneration Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 135. Asia-Pacific Age Related Macular Degeneration Drugs Market Share Forecast by Country (2027-2032) Table 136. Latin America Age Related Macular Degeneration Drugs Market Size Growth Rate (CAGR) by Country (W Tons): 2021 VS 2025 VS 2032 Table 137. Latin America Age Related Macular Degeneration Drugs Sales by Country (2021-2026) & (W Tons) Table 138. Latin America Age Related Macular Degeneration Drugs Sales Market Share by Country (2021-2026) Table 139. Latin America Age Related Macular Degeneration Drugs Sales Forecast by Country (2027-2032) & (W Tons) Table 140. Latin America Age Related Macular Degeneration Drugs Sales Market Share Forecast by Country (2027-2032) Table 141. Latin America Age Related Macular Degeneration Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. Latin America Age Related Macular Degeneration Drugs Market Size by Country (2021-2026) & (US$ Million) Table 143. Latin America Age Related Macular Degeneration Drugs Market Share by Country (2021-2026) Table 144. Latin America Age Related Macular Degeneration Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. Latin America Age Related Macular Degeneration Drugs Market Share Forecast by Country (2027-2032) Table 146. Middle East and Africa Age Related Macular Degeneration Drugs Market Size Growth Rate (CAGR) by Country (W Tons): 2021 VS 2025 VS 2032 Table 147. Middle East and Africa Age Related Macular Degeneration Drugs Sales by Country (2021-2026) & (W Tons) Table 148. Middle East and Africa Age Related Macular Degeneration Drugs Sales Market Share by Country (2021-2026) Table 149. Middle East and Africa Age Related Macular Degeneration Drugs Sales Forecast by Country (2027-2032) & (W Tons) Table 150. Middle East and Africa Age Related Macular Degeneration Drugs Sales Market Share Forecast by Country (2027-2032) Table 151. Middle East and Africa Age Related Macular Degeneration Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. Middle East and Africa Age Related Macular Degeneration Drugs Market Size by Country (2021-2026) & (US$ Million) Table 153. Middle East and Africa Age Related Macular Degeneration Drugs Market Share by Country (2021-2026) Table 154. Middle East and Africa Age Related Macular Degeneration Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. Middle East and Africa Age Related Macular Degeneration Drugs Market Share Forecast by Country (2027-2032) Table 156. Key Raw Materials Table 157. Raw Materials Key Suppliers Table 158. Age Related Macular Degeneration Drugs Distributors List Table 159. Age Related Macular Degeneration Drugs Customers List Table 160. Research Programs/Design for This Report Table 161. Authors List of This Report Table 162. Secondary Sources Table 163. Primary Sources List of Figures Figure 1. Age Related Macular Degeneration Drugs Image Figure 2. Global Age Related Macular Degeneration Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Age Related Macular Degeneration Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Age Related Macular Degeneration Drugs Sales (2021-2032) & (W Tons) Figure 5. Eylea Image Figure 6. Global Eylea Sales YoY Growth (2021-2032) & (W Tons) Figure 7. Avastin Image Figure 8. Global Avastin Sales YoY Growth (2021-2032) & (W Tons) Figure 9. Squalamine Image Figure 10. Global Squalamine Sales YoY Growth (2021-2032) & (W Tons) Figure 11. Conercept Image Figure 12. Global Conercept Sales YoY Growth (2021-2032) & (W Tons) Figure 13. Lampalizamab Image Figure 14. Global Lampalizamab Sales YoY Growth (2021-2032) & (W Tons) Figure 15. Lucentis Image Figure 16. Global Lucentis Sales YoY Growth (2021-2032) & (W Tons) Figure 17. Others Image Figure 18. Global Others Sales YoY Growth (2021-2032) & (W Tons) Figure 19. Global Age Related Macular Degeneration Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 20. Global Age Related Macular Degeneration Drugs Market Share by Type 2025 VS 2032 Figure 21. North America Age Related Macular Degeneration Drugs Sales Market Share in Volume by Type in 2025 Figure 22. North America Age Related Macular Degeneration Drugs Sales Market Share in Value by Type in 2025 Figure 23. Europe Age Related Macular Degeneration Drugs Sales Market Share in Volume by Type in 2025 Figure 24. Europe Age Related Macular Degeneration Drugs Sales Market Share in Value by Type in 2025 Figure 25. Asia-Pacific Age Related Macular Degeneration Drugs Sales Market Share in Volume by Type in 2025 Figure 26. Asia-Pacific Age Related Macular Degeneration Drugs Sales Market Share in Value by Type in 2025 Figure 27. Latin America Age Related Macular Degeneration Drugs Sales Market Share in Volume by Type in 2025 Figure 28. Latin America Age Related Macular Degeneration Drugs Sales Market Share in Value by Type in 2025 Figure 29. Middle East and Africa Age Related Macular Degeneration Drugs Sales Market Share in Volume by Type in 2025 Figure 30. Middle East and Africa Age Related Macular Degeneration Drugs Sales Market Share in Value by Type in 2025 Figure 31. Global Top 5 and 10 Age Related Macular Degeneration Drugs Players Market Share by Revenue in 2025 Figure 32. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 33. 50-60 Years Old Image Figure 34. Global 50-60 Years Old Sales YoY Growth (2021-2032) & (W Tons) Figure 35. 60-70 Years Old Image Figure 36. Global 60-70 Years Old Sales YoY Growth (2021-2032) & (W Tons) Figure 37. Others Image Figure 38. Global Others Sales YoY Growth (2021-2032) & (W Tons) Figure 39. Global Age Related Macular Degeneration Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 40. Global Age Related Macular Degeneration Drugs Market Share by Application 2025 VS 2032 Figure 41. North America Age Related Macular Degeneration Drugs Sales Market Share in Volume by Application in 2025 Figure 42. North America Age Related Macular Degeneration Drugs Sales Market Share in Value by Application in 2025 Figure 43. Europe Age Related Macular Degeneration Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Europe Age Related Macular Degeneration Drugs Sales Market Share in Value by Application in 2025 Figure 45. Asia-Pacific Age Related Macular Degeneration Drugs Sales Market Share in Volume by Application in 2025 Figure 46. Asia-Pacific Age Related Macular Degeneration Drugs Sales Market Share in Value by Application in 2025 Figure 47. Latin America Age Related Macular Degeneration Drugs Sales Market Share in Volume by Application in 2025 Figure 48. Latin America Age Related Macular Degeneration Drugs Sales Market Share in Value by Application in 2025 Figure 49. Middle East and Africa Age Related Macular Degeneration Drugs Sales Market Share in Volume by Application in 2025 Figure 50. Middle East and Africa Age Related Macular Degeneration Drugs Sales Market Share in Value by Application in 2025 Figure 51. North America Age Related Macular Degeneration Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Tons) Figure 52. North America Age Related Macular Degeneration Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. North America Age Related Macular Degeneration Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. North America Age Related Macular Degeneration Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Age Related Macular Degeneration Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Tons) Figure 56. Europe Age Related Macular Degeneration Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe Age Related Macular Degeneration Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Europe Age Related Macular Degeneration Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Age Related Macular Degeneration Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Tons) Figure 60. Asia-Pacific Age Related Macular Degeneration Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Age Related Macular Degeneration Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Asia-Pacific Age Related Macular Degeneration Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Age Related Macular Degeneration Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Tons) Figure 64. Latin America Age Related Macular Degeneration Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America Age Related Macular Degeneration Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Latin America Age Related Macular Degeneration Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Age Related Macular Degeneration Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Tons) Figure 68. Middle East and Africa Age Related Macular Degeneration Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa Age Related Macular Degeneration Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Middle East and Africa Age Related Macular Degeneration Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. Age Related Macular Degeneration Drugs Value Chain Figure 72. Key Raw Materials Price Figure 73. Manufacturing Cost Structure Figure 74. Age Related Macular Degeneration Drugs Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Eylea
  • Avastin
  • Squalamine
  • Conercept
  • Lampalizamab
  • Lucentis
  • Others
Applications
  • 50-60 Years Old
  • 60-70 Years Old
  • Others
Companies covered
  • Novartis
  • Roche
  • Bayer Healthcare
  • Regeneron Pharmaceuticals
  • Neurotech Pharmaceuticals
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Age Related Macular Degeneration Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Age Related Macular Degeneration Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Age Related Macular Degeneration Drugs Market by Type
  6. 1.3.1 Eylea
  7. 1.3.2 Avastin
  8. 1.3.3 Squalamine
  9. 1.3.4 Conercept
  10. 1.3.5 Lampalizamab
  11. 1.3.6 Lucentis
  12. 1.3.7 Others
  13. 1.4 Global Age Related Macular Degeneration Drugs Market Size by Type
  14. 1.4.1 Global Age Related Macular Degeneration Drugs Market Size Overview by Type (2021-2032)
  15. 1.4.2 Global Age Related Macular Degeneration Drugs Historic Market Size Review by Type (2021-2026)
  16. 1.4.3 Global Age Related Macular Degeneration Drugs Forecasted Market Size by Type (2027-2032)
  17. 1.5 Key Regions Market Size by Type
  18. 1.5.1 North America Age Related Macular Degeneration Drugs Sales Breakdown by Type (2021-2026)
  19. 1.5.2 Europe Age Related Macular Degeneration Drugs Sales Breakdown by Type (2021-2026)
  20. 1.5.3 Asia-Pacific Age Related Macular Degeneration Drugs Sales Breakdown by Type (2021-2026)
  21. 1.5.4 South America Age Related Macular Degeneration Drugs Sales Breakdown by Type (2021-2026)
  22. 1.5.5 Middle East and Africa Age Related Macular Degeneration Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Age Related Macular Degeneration Drugs Industry Trends
  2. 2.2 Age Related Macular Degeneration Drugs Industry Drivers
  3. 2.3 Age Related Macular Degeneration Drugs Industry Opportunities and Challenges
  4. 2.4 Age Related Macular Degeneration Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Age Related Macular Degeneration Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Age Related Macular Degeneration Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Age Related Macular Degeneration Drugs Price (2021-2026)
  4. 3.4 Global Age Related Macular Degeneration Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Age Related Macular Degeneration Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Age Related Macular Degeneration Drugs Company, Product Type & Application
  7. 3.7 Global Age Related Macular Degeneration Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Age Related Macular Degeneration Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Age Related Macular Degeneration Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Age Related Macular Degeneration Drugs Tier 1, Tier 2, and Tier 3
4 Age Related Macular Degeneration Drugs Regional Status and Outlook
  1. 4.1 Global Age Related Macular Degeneration Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Age Related Macular Degeneration Drugs Historic Market Size by Region
  3. 4.2.1 Global Age Related Macular Degeneration Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Age Related Macular Degeneration Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Age Related Macular Degeneration Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Age Related Macular Degeneration Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Age Related Macular Degeneration Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Age Related Macular Degeneration Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Age Related Macular Degeneration Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Age Related Macular Degeneration Drugs by Application
  1. 5.1 Age Related Macular Degeneration Drugs Market by Application
  2. 5.1.1 50-60 Years Old
  3. 5.1.2 60-70 Years Old
  4. 5.1.3 Others
  5. 5.2 Global Age Related Macular Degeneration Drugs Market Size by Application
  6. 5.2.1 Global Age Related Macular Degeneration Drugs Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Age Related Macular Degeneration Drugs Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Age Related Macular Degeneration Drugs Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Age Related Macular Degeneration Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Age Related Macular Degeneration Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Age Related Macular Degeneration Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Age Related Macular Degeneration Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Age Related Macular Degeneration Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Novartis
  2. 6.1.1 Novartis Company Information
  3. 6.1.2 Novartis Business Overview
  4. 6.1.3 Novartis Age Related Macular Degeneration Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Novartis Age Related Macular Degeneration Drugs Product Portfolio
  6. 6.1.5 Novartis Recent Developments
  7. 6.2 Roche
  8. 6.2.1 Roche Company Information
  9. 6.2.2 Roche Business Overview
  10. 6.2.3 Roche Age Related Macular Degeneration Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Roche Age Related Macular Degeneration Drugs Product Portfolio
  12. 6.2.5 Roche Recent Developments
  13. 6.3 Bayer Healthcare
  14. 6.3.1 Bayer Healthcare Company Information
  15. 6.3.2 Bayer Healthcare Business Overview
  16. 6.3.3 Bayer Healthcare Age Related Macular Degeneration Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Bayer Healthcare Age Related Macular Degeneration Drugs Product Portfolio
  18. 6.3.5 Bayer Healthcare Recent Developments
  19. 6.4 Regeneron Pharmaceuticals
  20. 6.4.1 Regeneron Pharmaceuticals Company Information
  21. 6.4.2 Regeneron Pharmaceuticals Business Overview
  22. 6.4.3 Regeneron Pharmaceuticals Age Related Macular Degeneration Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Regeneron Pharmaceuticals Age Related Macular Degeneration Drugs Product Portfolio
  24. 6.4.5 Regeneron Pharmaceuticals Recent Developments
  25. 6.5 Neurotech Pharmaceuticals
  26. 6.5.1 Neurotech Pharmaceuticals Company Information
  27. 6.5.2 Neurotech Pharmaceuticals Business Overview
  28. 6.5.3 Neurotech Pharmaceuticals Age Related Macular Degeneration Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Neurotech Pharmaceuticals Age Related Macular Degeneration Drugs Product Portfolio
  30. 6.5.5 Neurotech Pharmaceuticals Recent Developments
  31. 6.6 Allergan
  32. 6.6.1 Allergan Company Information
  33. 6.6.2 Allergan Business Overview
  34. 6.6.3 Allergan Age Related Macular Degeneration Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Allergan Age Related Macular Degeneration Drugs Product Portfolio
  36. 6.6.5 Allergan Recent Developments
7 North America by Country
  1. 7.1 North America Age Related Macular Degeneration Drugs Sales by Country
  2. 7.1.1 North America Age Related Macular Degeneration Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Age Related Macular Degeneration Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Age Related Macular Degeneration Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Age Related Macular Degeneration Drugs Market Size by Country
  6. 7.2.1 North America Age Related Macular Degeneration Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Age Related Macular Degeneration Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Age Related Macular Degeneration Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Age Related Macular Degeneration Drugs Sales by Country
  2. 8.1.1 Europe Age Related Macular Degeneration Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Age Related Macular Degeneration Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Age Related Macular Degeneration Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Age Related Macular Degeneration Drugs Market Size by Country
  6. 8.2.1 Europe Age Related Macular Degeneration Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Age Related Macular Degeneration Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Age Related Macular Degeneration Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Age Related Macular Degeneration Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Age Related Macular Degeneration Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Age Related Macular Degeneration Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Age Related Macular Degeneration Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Age Related Macular Degeneration Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Age Related Macular Degeneration Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Age Related Macular Degeneration Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Age Related Macular Degeneration Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Age Related Macular Degeneration Drugs Sales by Country
  2. 10.1.1 South America Age Related Macular Degeneration Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Age Related Macular Degeneration Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Age Related Macular Degeneration Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Age Related Macular Degeneration Drugs Market Size by Country
  6. 10.2.1 South America Age Related Macular Degeneration Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Age Related Macular Degeneration Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Age Related Macular Degeneration Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Age Related Macular Degeneration Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Age Related Macular Degeneration Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Age Related Macular Degeneration Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Age Related Macular Degeneration Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Age Related Macular Degeneration Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Age Related Macular Degeneration Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Age Related Macular Degeneration Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Age Related Macular Degeneration Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Age Related Macular Degeneration Drugs Value Chain Analysis
  2. 12.1.1 Age Related Macular Degeneration Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Age Related Macular Degeneration Drugs Production Mode & Process
  7. 12.2 Age Related Macular Degeneration Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Age Related Macular Degeneration Drugs Distributors
  10. 12.2.3 Age Related Macular Degeneration Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst